Enfusion, Inc. (NYSE:ENFN) Given Consensus Rating of “Reduce” by Brokerages

Shares of Enfusion, Inc. (NYSE:ENFN) have been given a consensus rating of “Reduce” by the five ratings firms that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating and two have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $10.00.

Separately, Stifel Nicolaus upped their target price on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th.

Enfusion Stock Up 1.5 %

Enfusion stock opened at $10.63 on Wednesday. The business has a 50 day moving average price of $9.70 and a two-hundred day moving average price of $9.00. Enfusion has a 12 month low of $7.52 and a 12 month high of $11.38. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of 265.82, a price-to-earnings-growth ratio of 3.98 and a beta of 0.97.

Insider Transactions at Enfusion

In other news, COO Neal Pawar sold 21,801 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total value of $218,664.03. Following the sale, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. The trade was a 1.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 36.44% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Enfusion

Hedge funds and other institutional investors have recently bought and sold shares of the business. RiverPark Advisors LLC bought a new position in shares of Enfusion in the second quarter worth about $68,000. Arizona State Retirement System bought a new position in Enfusion in the 2nd quarter worth approximately $86,000. Harbor Capital Advisors Inc. raised its position in Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after purchasing an additional 1,315 shares during the last quarter. Belvedere Trading LLC acquired a new position in Enfusion during the 3rd quarter worth $114,000. Finally, Paloma Partners Management Co bought a new position in Enfusion in the 3rd quarter valued at $157,000. 81.05% of the stock is owned by institutional investors and hedge funds.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.